Patents Issued in June 14, 2018
  • P-ETHOXY NUCLEIC ACIDS FOR LIPOSOMAL FORMULATION
    Publication number: 20180161360
    Abstract: Provided herein are therapeutic oligonucleotides that comprise at least one p-ethoxy backbone linkage but no more than 80% p-ethoxy backbone linkages. Provided herein are improved delivery systems for therapeutic oligonucleotides comprising a liposome that comprises neutral phospholipids and a p-ethoxy oligonucleotide that is entrapped in the liposome.
    Type: Application
    Filed: July 21, 2017
    Publication date: June 14, 2018
    Applicant: Bio-Path Holdings, Inc.
    Inventor: Peter NIELSEN
  • USE OF A BLOCK POLYMER COMPRISING A BLOCK OF POLY(3-(METHACRYLOYLAMINO)PROPYLTRIMETHYLAMMONIUM CHLORIDE) (PMAPTAC) FOR THE NEUTRALIZATION OF HEPARIN
    Publication number: 20180161361
    Abstract: The subject of the invention is use of block polymers with a block of poly(3-methacryloylpropyltrimethylammonium chloride) to direct neutralization of heparin, especially unfractionated heparin and low molecular weight heparins in the blood and other body fluids.
    Type: Application
    Filed: June 9, 2016
    Publication date: June 14, 2018
    Inventors: ANDRZEJ MOGIELNICKI, BARTLOMIEJ KALASKA, DARIUSZ PAWLAK, EMILIA SOKOLOWSKA, MARIA NOWAKOWSKA, KRZYSZTOF SZCZUBIALKA, KAMIL KAMINSKI
  • Controllably Degradable Compositions and Methods
    Publication number: 20180161362
    Abstract: Methods for treating, adhering, or sealing biological tissue are provided. The methods include combining solutions containing a polymer component and a dendrimer component capable of reacting with each other, and at least one of the components includes a substituent capable of photoreversible dimerization that can be reversibly dimerized. Drug delivery compositions and kits containing these two components also are provided.
    Type: Application
    Filed: January 29, 2018
    Publication date: June 14, 2018
    Inventors: Natalie Artzi, Elazer R. Edelman, Regina Kelmansky, Marc Mier Cervantes
  • Bi-Functional Co-Polymer Use for Ophthalmic and Other Topical and Local Applications
    Publication number: 20180161363
    Abstract: The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided.
    Type: Application
    Filed: February 6, 2018
    Publication date: June 14, 2018
    Inventors: Eugene Rex COOPER, David Maxwell KLEINMAN, Andrew LOXLEY, Mark A. MITCHNICK
  • CATIONIC COMPOUNDS AND THEIR USE AS ANTIMYCOTIC AND ANTIMICROBIAL AGENTS
    Publication number: 20180161364
    Abstract: The invention relates to cationic compounds and their use as antimicrobial and antimycotic agents, in particular as disinfectants and preservatives in ophthalmic preparations.
    Type: Application
    Filed: July 19, 2016
    Publication date: June 14, 2018
    Inventors: Stephan Reichl, Dörte Von Deylen, Christina Dreher, Frank Leßmann, Oliver Seidelmann
  • Phosphate-Binding Magnesium Salts And Uses Thereof
    Publication number: 20180161365
    Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.
    Type: Application
    Filed: February 12, 2018
    Publication date: June 14, 2018
    Inventors: Robert L. Lewis, Charles E. Day
  • METHODS OF OBTAINING MONONUCLEAR BLOOD CELLS AND USES THEREOF
    Publication number: 20180161366
    Abstract: Methods of obtaining mononuclear blood cells are provided. Also provided are methods of using the obtained cells for treating diseases such as cancer, infectious disease, autoimmune disease, allergy, and graft rejection.
    Type: Application
    Filed: May 19, 2016
    Publication date: June 14, 2018
    Applicants: Biokine Therapeutics Ltd., BioLineRx Ltd.
    Inventors: Amnon PELED, Yaron PEREG
  • THERAPY AND METHODS FOR INTRODUCING IMMATURE AND DENDRITIC CELLS AND/OR CYTOTOXIC T LYMPHOCYTE AND ANTI-TNF ANTIBODY FOR TREATMENT OF TUMORS
    Publication number: 20180161367
    Abstract: The invention relates to therapy and methods of applying the therapy to a patient. The invention includes the introduction of immature dendritic cells into the patient and the introduction of anti-TNF antibody into the patient. The immature dendritic cells are introduced intratumorally and/or through vessel and the anti-TNF antibody is introduced intratumorally and/or through vessel and/or subcutaneously. The immature dendritic cells can be formed by collecting monocyte cells from the patient and culturing the cells in a culture medium. The invention can be effective to regress, reduce or eliminate tumor cells in tumor tissue of the patients, including metastasized tumors. Further, the treatment of the invention is effective in the absence of conventional therapy, such as radiotherapy and chemotherapy.
    Type: Application
    Filed: February 6, 2018
    Publication date: June 14, 2018
    Inventor: KENICHIRO HASUMI
  • COMPOSITION AND METHODS FOR REGULATING INHIBITORY INTERACTIONS IN GENETICALLY ENGINEERED CELLS
    Publication number: 20180161368
    Abstract: Provided are engineered cells for adoptive therapy, including T cells. Also provided are methods and compositions for engineering and producing the cells, compositions containing the cells, and method for their administration to subjects. In some embodiments, the cells, such as T cells, contain genetically engineered antigen receptors that specifically bind to antigens, such as a chimeric antigen receptor (CAR). In some embodiments, the cells, such as a CAR-expressing T cell, contains an agent that is capable of reducing an inhibitory effect by repressing and/or disrupting a gene in an engineered cell, such as a gene involved in inhibiting the immune response. In some embodiments, features of the cells and methods provide for increased or improved activity, efficacy and/or persistence.
    Type: Application
    Filed: May 27, 2016
    Publication date: June 14, 2018
    Applicant: Juno Therapeutics, Inc.
    Inventor: Valerie ODEGARD
  • COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY
    Publication number: 20180161369
    Abstract: The present disclosure relates to compositions and methods for using cells having cellular immunotherapies comprising a composition of chimeric antigen receptor (CAR)-modified CD4+ T cells and a composition of CD8+ T cells modified with a distinct CAR in that the intracellular signaling component of the each CAR is different, wherein the modified CD4+ and CD8+ T cells have enhanced helper and effector functions, respectively, and together more effectively augment the immune response. Such cellular immunotherapies are useful in treating disease, such as cancer.
    Type: Application
    Filed: May 27, 2016
    Publication date: June 14, 2018
    Inventor: Stanley R. RIDDELL
  • METHODS FOR EXPANSION OR DEPLETION OF T-REGULATORY CELLS
    Publication number: 20180161370
    Abstract: The invention features methods of producing compositions enriched in Tregs and methods for treating immunological disorders using these compositions. The invention also features methods for producing compositions enriched in lymphocytes and depleted of Tregs and the use of these compositions in the treatment of proliferative disorders.
    Type: Application
    Filed: November 20, 2017
    Publication date: June 14, 2018
    Inventor: Denise L. FAUSTMAN
  • ENGINEERED NATURAL KILLER CELLS AND USES THEREOF
    Publication number: 20180161371
    Abstract: Disclosed herein are engineered natural killer cells that have been modified to express chimeric antigen receptors (CARs). The cells optionally contain other modifications that improve tumor specific cytotoxicity and homing to tumor sites. Also contemplated are methods for using the engineered natural killer cells to treat patients with cancer.
    Type: Application
    Filed: December 11, 2017
    Publication date: June 14, 2018
    Applicant: Onkimmune Limited
    Inventor: Michael Eamon Peter O'DWYER
  • COMPOSITION FOR TREATING BRAIN LESIONS
    Publication number: 20180161372
    Abstract: Some embodiments are directed to a pharmaceutical composition which includes a biocompatible polymer and a eukaryotic cell to be used as a drug for the prevention and/or treatment of tissue lesions of the central nervous system caused by cerebral vascular ischaemia. Some embodiments are also directed to a pharmaceutical kit which includes a biocompatible polymer and a eukaryotic cell for the prevention and/or treatment of tissue lesions of the central nervous system caused by cerebral vascular ischaemia. Some other embodiments can be used in particular in the human and veterinary pharmaceutical fields.
    Type: Application
    Filed: May 26, 2016
    Publication date: June 14, 2018
    Inventors: Myriam BERNAUDIN, Omar TOUZANI, Jérôme TOUTAIN, Marie-Sophie QUITTET, Denis BARRITAULT
  • METHODS AND DEVICES FOR THE PRODUCTION AND DELIVERY OF BENEFICIAL FACTORS FROM STEM CELLS
    Publication number: 20180161373
    Abstract: Provided herein are methods and devices related to inducing a population of self-renewing or senescent stem cells, to produce one or more beneficial factors for the treatment of a disease or disorder in an individual. Also provided are compositions and methods for inducing senescence, useful for inducing senescence in a population of stem cells, in order to produce one or more beneficial factors for the treatment of a disease or disorder in an individual. Methods and devices to control and customize the production of the beneficial factors for the requirements of a disease or disorder being treated are described. Also provided are factor production units for the production of the beneficial factors, and devices for the delivery of the beneficial factors to an individual in need.
    Type: Application
    Filed: June 2, 2016
    Publication date: June 14, 2018
    Inventors: Victoria LUNYAK, Meenakshi GAUR
  • USING AUTOLOGOUS MESENCHYMAL STEM CELLS TO TREAT MULTIPLE SYSTEM ATROPHY
    Publication number: 20180161374
    Abstract: This document provides methods and materials for treating multiple system atrophy in a mammal. Specifically, the methods comprises intrathecally administering to the mammal a composition comprising autologous mesenchymal stem cells (e.g. adipose deprived mesenchymal stem cells) to treat multiple system atrophy. Further disclosed is the composition comprising from about 5×10(6) to about 5×10(8) autologous mesenchymal stem cells.
    Type: Application
    Filed: June 15, 2016
    Publication date: June 14, 2018
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Wolfgang Singer, Phillip Low
  • Therapeutic method for repairing damaged pancreas
    Publication number: 20180161375
    Abstract: The invention is a therapeutic method for repairing damaged pancreas. The method comprises administrating Epigallocatechin gallate (EGCG) of green tea and a plurality of adipose-derived stem cells (ADSC). And Epigallocatechin gallate (EGCG) of green tea enhances the ability of the adipose-derived stem cells to repair damaged tissue.
    Type: Application
    Filed: February 6, 2018
    Publication date: June 14, 2018
    Inventors: Shaw-Yih Liou, Chih-Yang Huang, Tsai-Jui Liou, Tung-Sheng CHEN, I-Te Liou
  • COMPOSITIONS AND METHODS FOR NEURONAL DIFFERENTIATION OF CELLS
    Publication number: 20180161376
    Abstract: This invention relates to compositions and methods for enhanced differentiation of cells towards a neuronal phenotype. Neuronal cells produced using the compositions and methods may be used in the study of neurological diseases and disorders, for drug screening and for therapeutic purposes. The invention provides a method for producing a neuron comprising inducing neuronal differentiation of a cell, wherein neuronal differentiation in said cell is induced by inhibition of Small Mothers Against Decapentaplegic (SMAD) signaling and nitric oxide synthase (NOS) in said cell.
    Type: Application
    Filed: December 8, 2015
    Publication date: June 14, 2018
    Inventors: Carolyn Mary SUE, Steven GAO, Nicholas BLAIR
  • METHOD OF TREATING NEUROLOGICAL DISORDERS WITH STEM CELL THERAPY
    Publication number: 20180161377
    Abstract: A method for isolating self-renewable stem cells from pluripotent stem cells (embryonic or induced) by treating the pluripotent stem cells with a combination of epidermal growth factor and basic growth factor, wherein upon treatment, the pluripotent stem cells differentiate into self-renewable neural stem cells. The self-renewable stem cells may be further induced to dopaminergic neurons through treatment with dopaminergic inducing media. The dopaminergic neurons may be administered in a cell suspension, alone or in combination with purified glial cells, directly into the brain tissue of patients suffering from neurological disorders.
    Type: Application
    Filed: December 9, 2017
    Publication date: June 14, 2018
    Applicant: NEONEURON LLC
    Inventor: Marcel M Daadi
  • AGENT FOR PROMOTING MIGRATION OF PLURIPOTENT STEM CELLS
    Publication number: 20180161378
    Abstract: An agent for promoting migration of pluripotent stem cells containing an extract from inflamed tissues inoculated with vaccinia virus. An extract from inflamed tissues inoculated with vaccinia virus promotes migration of Muse cells. Thus, the agent for promoting migration of pluripotent stem cells for various diseases to which migration of pluripotent stem cells may have an advantageous effect.
    Type: Application
    Filed: May 27, 2016
    Publication date: June 14, 2018
    Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    Inventors: Mari DEZAWA, Mieko OHTSU
  • COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING TISSUE INJURY AND DISEASE
    Publication number: 20180161379
    Abstract: The present invention provides novel compositions comprising multipotent cells or microvascular tissue, wherein the cells or tissue has been sterilized and/or treated to inactivated viruses, and related methods of using these compositions to treat or prevent tissue injury or disease in an allogeneic subject.
    Type: Application
    Filed: January 8, 2018
    Publication date: June 14, 2018
    Inventors: Dale R. PETERSON, Ralph-Heiko MATTERN, Corey WILSON, Kevin L. OHASHI, Lael J. PICKETT, Glen GONG, Mohammad A. EL-KALAY
  • THERAPEUTIC TREATMENT OF SKIN DISEASE WITH RECOMBINANT COMMENSAL SKIN MICROORGANISMS
    Publication number: 20180161380
    Abstract: The invention relates to methods for treating or preventing abnormal skin conditions in a human in need thereof, comprising administering a cell culture composition comprising a living culture of bacteria comprising at least one engineered strain that produces a recombinant polypeptide for therapeutic treatment of the abnormal skin condition. The invention also relates to pharmaceutical compositions containing, as the active principle, engineered microorganisms expressing non-vaccinogenic pharmacologically active recombinant therapeutic polypeptides in order to treat or prevent abnormal skin conditions.
    Type: Application
    Filed: May 28, 2015
    Publication date: June 14, 2018
    Inventors: Azim Momin Munivar, Travis Michael Whitfill
  • NUTRITIONAL COMPOSITIONS AND METHODS FOR REDUCING THE OCCURRENCE OR SEVERITY OF VIRAL INFECTIONS, BACTERIAL INFECTIONS AND VIRAL AND BACTERIAL CO-INFECTIONS
    Publication number: 20180161381
    Abstract: The present disclosure is directed to methods for reducing the risk of developing or reducing the severity of a viral infection, bacterial infection, or viral and bacterial co-infection in a subject comprising administering to the subject a nutritional composition comprising an effective amount of a soluble mediator preparation derived from a late-exponential growth phase of a probiotic culture, such as Lactobacillus rhamnosus GG (LGG). The present disclosure, in certain embodiments, is directed to methods for reducing inflammation in a subject with a viral infection, bacterial infection, or viral and bacterial co-infections, comprising administering to the subject a nutritional composition comprising an effective amount of a soluble mediator preparation from a late-exponential growth phase of a probiotic culture, such as LGG.
    Type: Application
    Filed: December 12, 2016
    Publication date: June 14, 2018
    Inventors: Sarmauli Manurung, Gabriele Gross, Teartse Tim Lambers, Eric A.F. van Tol
  • PREBIOTIC COMPOSITIONS COMPRISING ONE OR MORE TYPES OF BACTERIOPHAGE
    Publication number: 20180161382
    Abstract: Disclosed herein are compositions that comprise one or more types of bacteriophage and methods of using such bacteriophages as a prebiotic to promote the growth of beneficial bacteria by decreasing harmful bacterial populations and releasing nutrients into the environment for good bacteria in the digestive system of an individual.
    Type: Application
    Filed: December 11, 2017
    Publication date: June 14, 2018
    Inventors: John Deaton, Elizabeth Ertle, Hilton Grant Dawson
  • NATURAL PHARMACEUTICAL COMPOSITION FOR TREATING MENOPAUSAL MENTAL DEPRESSION AND ATYPICAL DEPRESSIVE DISORDER AND APPLICATION THEREOF
    Publication number: 20180161383
    Abstract: The present disclosure discloses a pharmaceutical composition for treating menopausal mental depression and atypical depressive disorder and an application thereof. The composition is composed of the following components in percentage by mass: 70%-97.5% of sea buckthorn pulp oil and 2.5%-30% of total panax notoginseng saponins from stem and leave. The application is use of the pharmaceutical composition for preparing drugs and/or health care products used for treating menopause, the menopausal mental depression or the atypical depressive disorder.
    Type: Application
    Filed: January 12, 2018
    Publication date: June 14, 2018
    Inventors: Xiazhen WEI, Lanlan SONG, Shaohua HAN
  • Vaporized Medicants and Methods of Use
    Publication number: 20180161384
    Abstract: A method and formulation for delivering an active analgesic compound, such as an opiate, in a vaporized state using low temperatures to vaporize the formulation. The formulation contains an inert non-reactive compound that lowers the heat of vaporization of the formulation, and the active compound. The formulation may optionally contain glycerin, alcohol, and/or water. Examples of inert non-reactive compounds that can sufficiently lower the heat of vaporization of the formulation include propylene glycol, vegetable glycerin and polysorbate. The formulation can be vaporized using a hand-held low temperature vaporizer or atomizer.
    Type: Application
    Filed: January 26, 2018
    Publication date: June 14, 2018
    Inventors: Alexander Chinhak Chong, William P. Bartkowski, Marshall A. Thompson
  • COMPOSITIONS AND METHODS FOR MAINTAINING OR ENHANCING HOMEOSTASIS OR FUNCTION OF FEMALE LOWER REPRODUCTIVE TRACT
    Publication number: 20180161385
    Abstract: The present disclosure provides compositions and methods for making and using topical compositions comprised of an isotonic, biome-friendly solution containing xylose and/or a Salvia extract. The compositions are useful for, for example, maintaining or enhancing female lower reproductive tract (LRT) homeostasis and physiological function. In particular, topical compositions of this disclosure can be formulated for use as a freshening, menopausal, fertility, and/or perineal composition.
    Type: Application
    Filed: February 12, 2018
    Publication date: June 14, 2018
    Inventors: Joanna E. ELLINGTON, G. Dennis CLIFTON
  • PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DEPRESSION AND PREPARATION METHOD THEREOF
    Publication number: 20180161386
    Abstract: Disclosed is a pharmaceutical composition for the treatment of Depression, wherein the pharmaceutical composition is comprised of the following herbs in weight parts: 2-10 parts Ramulus Cinnamomi, 2-10 parts Rhizoma Zingiberis, 2-10 parts Fructus Schisandrae Chinensis, 2-8 parts Semen Ziziphi Spinosae, 2-8 parts Radix Codonopsis, 1-3 parts Rhizoma Dioscoreae, 0.5-2.5 parts Flos Inulae, 1-3 parts Caulis Bambusae in Taenia, 1-3 parts Fructus Trichosanthis, 1.5-4 parts Caulis Polygoni Multiflori, 1.5-4 parts Radix Ophiopogonis, 2-8 parts Radix Rehmanniae, 1.5-4 parts Cortex Moutan Radicis, 0.5-2.5 parts Fructus Gardeniae, 0.5-2.5 parts Herba Lophatheri, and 0.2-1.5 parts Folium Sennae. Also disclosed is a method for preparing the pharmaceutical composition as described above for treatment of depression.
    Type: Application
    Filed: June 3, 2016
    Publication date: June 14, 2018
    Inventors: Luping YU, Wencheng WANG
  • COMPOSITIONS OF HERBAL FORMULATIONS AND USES THEREOF
    Publication number: 20180161387
    Abstract: Disclosed herein are herbal formulations for relief from symptoms of skin disease. The formulations can also be combined with an active or inactive pharmaceutical ingredient, and/or a pharmaceutically acceptable excipient.
    Type: Application
    Filed: February 6, 2018
    Publication date: June 14, 2018
    Applicant: HAUS BIOCEUTICALS, INC.
    Inventors: Tomy YESUDAS, Philip ALEX, Michael CENTOLA, Adam Joshua PAYNE
  • SUBSTANCE P, MAST CELL DEGRANULATION INHIBITORS, AND PERIPHERAL NEUROPATHY
    Publication number: 20180161388
    Abstract: Described herein are methods of using Substance P, mast cell degranulation inhibitors, or combinations thereof to delay the onset of, to reverse, or to reduce the risk of acquiring complications associated with diabetes. Also provided herein are methods for accelerating wound healing in diabetic subjects using Substance P, mast cell degranulation inhibitors, or combinations thereof.
    Type: Application
    Filed: May 17, 2016
    Publication date: June 14, 2018
    Inventors: Lijun SUN, Aristidis VEVES
  • R-SPONDIN AGONIST-MEDIATED HAIR GROWTH
    Publication number: 20180161389
    Abstract: Cosmetic skin and hair care compositions for enhancing the growth and appearance of mammalian hair in an individual are provided, which compositions comprise a dose of an R-spondin agonist effective to promote anagen phase of the hair cycle.
    Type: Application
    Filed: January 8, 2016
    Publication date: June 14, 2018
    Inventors: Jill Helms, Girija Dhamdhere, Andrew A. Smith, Arie Abo, Anthony E. Oro
  • ADIPONECTIN PEPTIDOMIMETICS FOR TREATING OCULAR DISORDERS
    Publication number: 20180161390
    Abstract: Provided herein are compositions and methods for treating dry eye or an ocular disease associated with inflammation in a subject in need thereof. The therapeutic compositions comprise an adiponectin peptidomimetic compound, and a pharmaceutically acceptable carrier. Also provided are methods for alleviating one or more symptoms or clinical signs of dry eye or an ocular disease associated with inflammation in a subject in need thereof.
    Type: Application
    Filed: April 29, 2016
    Publication date: June 14, 2018
    Applicant: Allysta Pharmaceuticals, Inc.
    Inventor: Henry HSU
  • INHIBITORS OF BCL-2
    Publication number: 20180161391
    Abstract: A protease resistant polypeptide includes an amino acid sequence that has a sequence identity at least 80% homologous to about 10 to 80 consecutive amino acids of SEQ ID NO:1.
    Type: Application
    Filed: May 23, 2017
    Publication date: June 14, 2018
    Inventors: Clark Distelhorst, Yiping Rong
  • THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN
    Publication number: 20180161392
    Abstract: The present invention relates to a p75NTR neurotrophin binding protein, p75NTR(NBP), for use in the treatment of pain and/or a symptom of pain.
    Type: Application
    Filed: August 18, 2017
    Publication date: June 14, 2018
    Inventor: Simon WESTBROOK
  • PRG4 FOR TREATING GOUT AND ITS SYMPTOMS
    Publication number: 20180161393
    Abstract: Disclosed are methods of treating gout in a subject and methods of reducing joint pain in a subject with gout or pseudogout, comprising administering to the subject a composition comprising PRG4 or a biologically active fragment thereof.
    Type: Application
    Filed: November 9, 2017
    Publication date: June 14, 2018
    Inventors: Gregory D. Jay, Khaled Elsaid
  • Methods and Related Kits for Treating and Regenerating Tooth Pulp and Periapical Tissues in a Mammal
    Publication number: 20180161394
    Abstract: In one embodiment, a method of regenerating tooth pulp in a mammal is provided. The method comprises removing at least a portion the existing tooth pulp of a mammal and adding amelogenin protein to the existing tooth pulp of the mammal to regenerate tooth pulp in a mammal. In another embodiment, a method of treating necrotic tooth pulp of a mammal is provided. The method comprises providing at least one necrotic tooth pulp of a mammal with an amelogenin protein. In yet another embodiment, a kit for regenerating tooth pulp in a mammal is provided. The kit comprises an adequate amount of amelogenin protein for regenerating tooth pulp in a mammal and instructions for applying the amelogenin protein to at least one tooth pulp of the mammal.
    Type: Application
    Filed: February 9, 2018
    Publication date: June 14, 2018
    Inventors: Maha Mohamed Fouad Mounir, Malcolm L. Snead
  • METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
    Publication number: 20180161395
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of Alzheimer's disease. In particular the present invention relates to a method of treating Alzheimer's disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a vector which comprises a nucleic acid molecule encoding for a polypeptide which is a soluble member of the APP (amyloid precursor protein) family.
    Type: Application
    Filed: June 10, 2016
    Publication date: June 14, 2018
    Inventors: Romain FOL, Jerome BRAUDEAU, Nathalie CARTIER, Christian BUCHHOLZ, Abel TOBIAS, Ulrike MUELLER
  • NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME
    Publication number: 20180161396
    Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (MAGEA1). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Application
    Filed: December 7, 2017
    Publication date: June 14, 2018
    Inventors: Leonie ALTEN, Sebastian BUNK, Dominik MAURER, Claudia WAGNER
  • METHODS FOR MODULATING AN INFLAMMATORY RESPONSE
    Publication number: 20180161397
    Abstract: The inventive subject matter relates to novel methods for modulating an immune response in an animal, which comprises administering to said animal an effective amount of an agent that increases IL-27R/WSX-1 activity. Further, the inventive subject matter relates to pharmaceutical compositions comprising an effective amount of an agent that increases IL-27R/WSX-1 activity.
    Type: Application
    Filed: January 30, 2018
    Publication date: June 14, 2018
    Inventors: Christopher A. HUNTER, Alejandro VILLARINO
  • COMPOSITION CONTAINING INDUCER OF SIRT1 EXPRESSION FOR PREVENTING OR TREATING SEPSIS OR SEPTIC SHOCK
    Publication number: 20180161398
    Abstract: The present invention relates to a composition containing an inducer of SIRT1 (silent mating type information regulation 2 homolog) expression for preventing or treating sepsis or septic shock. The inducer of SIRT1 expression can remarkably reduce the mortality caused by sepsis or septic shock by reducing pro-inflammatory cytokines and increasing anti-inflammatory cytokines. Therefore, the inducer of SIRT1 expression is useful for preventing or treating sepsis or septic shock.
    Type: Application
    Filed: February 6, 2018
    Publication date: June 14, 2018
    Inventors: Myung Kwan HAN, Chae Hwa YOO, Eun Kyung SONG, Seung Ok LEE
  • TREATMENT OF CANCER WITH IMMUNE STIMULATORS
    Publication number: 20180161399
    Abstract: The present invention provides compositions and methods for treating cancer or a metastasis thereof in a subject. In some embodiments, the methods involve administering a composition comprising therapeutically effective amount of at least one immune stimulator to the subject. In some embodiments, a combination of at least two immune stimulators is used for the treatment. In some embodiments, the combination includes an alpha thymosin peptide and an additional immune stimulator, and/or optionally one or more additional anti-cancer agents.
    Type: Application
    Filed: July 5, 2017
    Publication date: June 14, 2018
    Inventors: Robert S. KING, Cynthia W. TUTHILL, Friedhelm BLOBEL
  • ANTIDIABETIC ORAL INSULIN BIGUANIDE COMBINATION
    Publication number: 20180161400
    Abstract: Pharmaceutical dosage forms, comprising insulin, a delivery agent that facilitates insulin transport in a therapeutically effective amount to the bloodstream and a biguanide, such as metformin, are disclosed for oral administration to a patient for the treatment of diabetes.
    Type: Application
    Filed: July 10, 2017
    Publication date: June 14, 2018
    Inventors: Ehud ARBIT, Michael GOLDBERG, Steven DINH
  • Novel Formulations of PTHrP Analogue
    Publication number: 20180161401
    Abstract: The present invention provides a non-buffered, neutral pH easily prepared, storage-stable composition containing a parathyroid hormone-related protein (PTHrP) analogue and methods of using a PTHrP analogue and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition has a non-buffered neutral pH which avoids injection site reactions and is easy to prepare and storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.
    Type: Application
    Filed: July 5, 2016
    Publication date: June 14, 2018
    Inventor: Zheng Xin Dong
  • TRUNCATED VON WILLEBRAND FACTOR POLYPEPTIDES FOR TREATING HEMOPHILIA
    Publication number: 20180161402
    Abstract: The invention relates to a polypeptide comprising a truncated von Willebrand Factor (VWF) for use in the treatment of a blood coagulation disorder, wherein the polypeptide carries a half-life extending moiety and is administered in molar excess over Factor VIII and/or endogenous VWF.
    Type: Application
    Filed: May 20, 2016
    Publication date: June 14, 2018
    Inventors: Stefan SCHULTE, Hubert METZNER, Sabine PESTEL, Thomas WEIMER
  • ADENO-ASSOCIATED VIRUS FACTOR VIII VECTORS
    Publication number: 20180161403
    Abstract: The invention provides improved adeno-associated virus (AAV) Factor VIII (FVIII) vectors, including AAV FVIII vectors that produce a functional Factor VIII polypeptide and AAV FVIII vectors with high expression activity.
    Type: Application
    Filed: November 17, 2017
    Publication date: June 14, 2018
    Inventors: Amit Nathwani, Jenny McIntosh, Edward Tuddenham
  • CONTROLLED RELEASE SYSTEM FOR PULMONARY DELIVERY OF SURFACTANT PROTEIN D
    Publication number: 20180161404
    Abstract: A controlled release system includes surfactant protein D (SPD) and a carrier suitable for controlled release that can be polylactic-co-glycolic acid (PLGA). The system can be in the form of a nanoparticle. A pharmaceutical composition includes the system and a pharmaceutically acceptable carrier. Methods of treatment of a disease, disorder or condition associated with a decreased level of SPD in a subject, or for pulmonary delivery of SPD, include administering the pharmaceutical composition to a subject in need of such treatment.
    Type: Application
    Filed: June 9, 2016
    Publication date: June 14, 2018
    Inventors: Joseph KOST, Tamar TRAITEL, Riki GOLDBART, Shani ATTIAS, Paul Scot KINGMA, Jeffrey A. WHITSETT, Giora ENDEN
  • IMPROVED METHODS FOR TREATING OCULAR DISEASES BY GENE THERAPY
    Publication number: 20180161405
    Abstract: The invention relates to a pharmaceutical composition comprising a recombinant adeno-associated virus (r AAV) vector carrying a nucleic acid sequence encoding a functional gene under the control of regulatory sequences which express the product of said gene in the retinal cells, for use in a method for preventing or treating an inherited retinal degenerative disorder associated with mutations in said gene, wherein the pharmaceutical composition is administered during the same operative period by at least one subretinal injection in each quadrant of retina of the patient in need thereof and wherein said quadrants consist of infero-temporal retina, supero-temporal retina, infero-nasal retina and supero-nasal retina.
    Type: Application
    Filed: June 3, 2016
    Publication date: June 14, 2018
    Inventors: Guylène LE MEUR, Michel WEBER, Véronique BLOUIN
  • Botulinum Neurotoxin Compositions
    Publication number: 20180161406
    Abstract: Present invention provides a stable pharmaceutical composition comprising botulinum neurotoxin, anesthetic in a buffer. Present invention also provides a process for the preparation of the stable pharmaceutical composition. The botulinum neurotoxin is stabilized by the formation of complex between the toxin and anesthetic. The present invention further provides a method for treating wrinkles using the said pharmaceutical composition.
    Type: Application
    Filed: December 8, 2016
    Publication date: June 14, 2018
    Applicant: Prime Bio, Inc
    Inventor: Bal Ram Singh
  • Novel Method of Treating Macular Degeneration using Botulinum Toxin-Based Pharmaceuticals
    Publication number: 20180161407
    Abstract: Formulations and methods of treatment are disclosed for prevention and/or treatment of visual loss from age-related macular degeneration. The disclosed formulations include botulinum neurotoxin (e.g., botulinum neurotoxin or a fragment thereof, either in pure form or with one or more peptide fragments and/or neurotoxin associated proteins). In some embodiments, the disclosed formulations also include one or more anti-VEGF agents. The disclosed formulations may be applied to an intraocular or extraocular region of a patient.
    Type: Application
    Filed: December 7, 2017
    Publication date: June 14, 2018
    Inventor: Gary E. Borodic
  • SITE-SPECIFIC POLYETHYLENE GLYCOLYLATED (PEGYLATED) ASPARAGINASE, PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20180161408
    Abstract: The present application discloses a PEGylated asparaginase and use thereof. In this application, the polyethylene glycol (PEG) is coupled to the N-terminal amino of 1 or 2 subunits of L-asparaginase, and the molecular weight of the PEG is 30-40 KDa. The PEG is preferably branched and has an aldehyde group serving as an activating group. The PEGylated asparaginase is useful in the preparation of anti-tumor drugs.
    Type: Application
    Filed: February 3, 2015
    Publication date: June 14, 2018
    Applicants: ZONHON BIOPHARMA INSTITUTE INC., GENSUN INSTITUTE OF BIOMEDICINE CO., LTD.
    Inventors: Bruce Yong MA, Jun WANG, He WANG, Chunlin XU, Yifei CHEN, Yaofang WANG
  • Method of Treating Proteinuria in Pregnancy
    Publication number: 20180161409
    Abstract: A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and a method for preparing the therapeutic agent are disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or by other methods. Further, a method of using the presence of chymotrypsin in the maternal GI tract as a biomarker, to determine the likelihood of developing preeclampsia, a pregnancy induced hypertension, and eclampsia/toxemia is disclosed.
    Type: Application
    Filed: February 6, 2018
    Publication date: June 14, 2018
    Inventor: Joan Fallon